Spotlight on Gynecology/Obstetrics

Credits: 1.00 CNE / CPE
Nursing and Pharmacy Provisions of Care for HR+/HER2− Advanced or Metastatic Breast Cancer: Spotlight on CDK 4/6 Inhibitors
Michael Brandt, PharmD, FASHP
AXIS

Nursing and Pharmacy Provisions of Care for HR+/HER2− Advanced or Metastatic Breast Cancer: Spotlight on CDK 4/6 Inhibitors

Start

Activity Details

Free CPE/CNE
1.0 Contact Hour
Released: August 27, 2018
Expires: August 26, 2019
1 hour to complete

Provided by

This educational activity is provided by

Target Audience

This activity is intended for oncology nurses, advanced practitioners, pharmacists, pharmacy technicians, and other allied healthcare professionals involved in the team-based management of breast cancer.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Discuss the risks, benefits, and differentiation points among CDK 4/6 inhibitors for the treatment of HR-positive/HER2-negative advanced breast cancer with the healthcare team and patients.
  • Evaluate proper dosing and administration of oral CDK 4/6 inhibitors used in the treatment of HR-positive/HER2-negative advanced breast cancer.
  • Enhance patient education through shared decision-making strategies regarding therapy selection and the importance of oral therapy compliance to maximize therapeutic outcomes.
  • Educate patients on potential adverse events associated with CDK 4/6 inhibitors.
  • Develop strategies to anticipate, monitor and manage adverse events with oral CDK 4/6 inhibitors for the treatment of HR-positive/HER2-negative advanced breast cancer to maximize the benefits of these therapies.

Activity Description

The American Cancer Society estimated that in 2017 there were 255,180 new cases of breast cancer and 41,070 deaths due to breast cancer in the United States. Nearly 80% of patients with advanced breast cancer have the HER2-negative subtype and, therefore, are not candidates for HER2-targeting therapies.

Significant advances include the development of agents that target critical pathways involved in resistance to endocrine therapy, such as cyclin-dependent kinase (CDK) 4/6 inhibitors. Differentiating among the agents that comprise this novel class will be essential practice skills that oncology advanced practitioners such as nurses and pharmacists will need to become more familiar with to advance patient care and support.

New oral agents are revolutionizing breast cancer care, and data show that patient adherence to the full duration of therapy is critical to realize the positive effects of these agents on tumor control and patient survival. Nurses and pharmacists can play a critical role in improving patient adherence to oral therapy, from treatment decision support and monitoring to management and patient counseling.

This activity will review these oral therapies, including risk and benefits, barriers to adherence, side effect monitoring and management and patient counseling on aspects such as dosing and safe handling of oral therapies. This will be coupled with education about shared decision-making strategies to achieve increased patient satisfaction, better adherence to treatment plans, greater treatment engagement, and better quality decision making.

Statement of Educational Need

The goal of this activity is to provide education about oral CDK 4 and 6 inhibitors for the treatment of HR+/HER2− advanced or metastatic breast cancer so nurses, pharmacists, and other healthcare professionals are able to educate, counsel, and support patients regarding benefits, dosing, adherence, and side effects of therapies to make informed decisions with the goal of improving patient outcomes.

Faculty

Pharmacy Co-Chairperson
Michael L. Brandt, PharmD, FASHP
Oncology Infusion Pharmacist
Cancer and Blood Specialties Center
Rockwood Clinic, MultiCare Health System
Spokane, Washington


Nurse Co-Chairperson
Jacquelyn H. Lauria, MS, RN, APN-C, AOCNP®
Advanced Practice Nurse
Rutgers Cancer Institute of New Jersey
Stacy Goldstein Breast Center
New Brunswick, New Jersey

Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or Presenter

Reported Financial Relationship

Michael L. Brandt, PharmD, FASHP

Michael L. Brandt, PharmD, FASHP, has no real or apparent conflicts of interest to report

Jacquelyn H. Lauria, MS, RN, APN-C, AOCNP®

Jacquelyn H. Lauria, MS, RN, APN-C, AOCNP®, reported a financial interest/relationship or affiliation in the form of Serve(d) as a speaker or a member of a speakers bureau for: PUMA Biotechnology


The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Stephanie Sutphin, PharmD; and Marilyn Haas, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Credit Designation for Pharmacists/Pharmacy Technicians
This application-based activity is approved for 1.0 contact hour of continuing pharmacy education credit (JA4008106-0000-18-039-H01-P and JA4008106-0000-18-039-H01-T).

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. Pharmacists – your record will be loaded to CPE Monitor.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at info@axismeded.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Gynecology/Obstetrics Presentations

1.00 CNE / CPE
AXIS
Nursing and Pharmacy Provisions of Care for HR+/HER2− Advanced or Metastatic Breast Cancer: Spotlight on CDK 4/6 Inhibitors

Nursing and Pharmacy Provisions of Care for HR+/HER2− Advanced or Metastatic Breast Cancer: Spotlight on CDK 4/6 Inhibitors

Start

Activity Details

Free CPE/CNE
1.0 Contact Hour
Released: August 27, 2018
Expires: August 26, 2019
1 hour to complete

Provided by

This educational activity is provided by

Target Audience

This activity is intended for oncology nurses, advanced practitioners, pharmacists, pharmacy technicians, and other allied healthcare professionals involved in the team-based management of breast cancer.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Discuss the risks, benefits, and differentiation points among CDK 4/6 inhibitors for the treatment of HR-positive/HER2-negative advanced breast cancer with the healthcare team and patients.
  • Evaluate proper dosing and administration of oral CDK 4/6 inhibitors used in the treatment of HR-positive/HER2-negative advanced breast cancer.
  • Enhance patient education through shared decision-making strategies regarding therapy selection and the importance of oral therapy compliance to maximize therapeutic outcomes.
  • Educate patients on potential adverse events associated with CDK 4/6 inhibitors.
  • Develop strategies to anticipate, monitor and manage adverse events with oral CDK 4/6 inhibitors for the treatment of HR-positive/HER2-negative advanced breast cancer to maximize the benefits of these therapies.

Activity Description

The American Cancer Society estimated that in 2017 there were 255,180 new cases of breast cancer and 41,070 deaths due to breast cancer in the United States. Nearly 80% of patients with advanced breast cancer have the HER2-negative subtype and, therefore, are not candidates for HER2-targeting therapies.

Significant advances include the development of agents that target critical pathways involved in resistance to endocrine therapy, such as cyclin-dependent kinase (CDK) 4/6 inhibitors. Differentiating among the agents that comprise this novel class will be essential practice skills that oncology advanced practitioners such as nurses and pharmacists will need to become more familiar with to advance patient care and support.

New oral agents are revolutionizing breast cancer care, and data show that patient adherence to the full duration of therapy is critical to realize the positive effects of these agents on tumor control and patient survival. Nurses and pharmacists can play a critical role in improving patient adherence to oral therapy, from treatment decision support and monitoring to management and patient counseling.

This activity will review these oral therapies, including risk and benefits, barriers to adherence, side effect monitoring and management and patient counseling on aspects such as dosing and safe handling of oral therapies. This will be coupled with education about shared decision-making strategies to achieve increased patient satisfaction, better adherence to treatment plans, greater treatment engagement, and better quality decision making.

Statement of Educational Need

The goal of this activity is to provide education about oral CDK 4 and 6 inhibitors for the treatment of HR+/HER2− advanced or metastatic breast cancer so nurses, pharmacists, and other healthcare professionals are able to educate, counsel, and support patients regarding benefits, dosing, adherence, and side effects of therapies to make informed decisions with the goal of improving patient outcomes.

Faculty

Pharmacy Co-Chairperson
Michael L. Brandt, PharmD, FASHP
Oncology Infusion Pharmacist
Cancer and Blood Specialties Center
Rockwood Clinic, MultiCare Health System
Spokane, Washington


Nurse Co-Chairperson
Jacquelyn H. Lauria, MS, RN, APN-C, AOCNP®
Advanced Practice Nurse
Rutgers Cancer Institute of New Jersey
Stacy Goldstein Breast Center
New Brunswick, New Jersey

Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or Presenter

Reported Financial Relationship

Michael L. Brandt, PharmD, FASHP

Michael L. Brandt, PharmD, FASHP, has no real or apparent conflicts of interest to report

Jacquelyn H. Lauria, MS, RN, APN-C, AOCNP®

Jacquelyn H. Lauria, MS, RN, APN-C, AOCNP®, reported a financial interest/relationship or affiliation in the form of Serve(d) as a speaker or a member of a speakers bureau for: PUMA Biotechnology


The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Stephanie Sutphin, PharmD; and Marilyn Haas, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Credit Designation for Pharmacists/Pharmacy Technicians
This application-based activity is approved for 1.0 contact hour of continuing pharmacy education credit (JA4008106-0000-18-039-H01-P and JA4008106-0000-18-039-H01-T).

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. Pharmacists – your record will be loaded to CPE Monitor.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at info@axismeded.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / CNE
Postgraduate Institute for Medicine
A System-Based Patient-Centered Approach to HER2-Positive Breast Cancer

A System-Based Patient-Centered Approach to HER2-Positive Breast Cancer

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit
0.5 ANCC contact hour
0.5 APRN contact hour
Released: February 20, 2018
Expires: February 20, 2019
0.5 hour to complete

Jointly Provided By

Target Audience

Oncology clinicians, including physicians, nurses, nurse practitioners, and physician assistants

Learning Objectives

After completing this educational activity, the participant will demonstrate the ability to:

  1. Routinely use ASCO/CAP13 guidelines to determine HER2 status that guide management and assist in evaluating risk
  2. Integrate evolving targeted treatment paradigms into clinical practice for patients with HER2-positive breast cancer, based on efficacy and safety
  3. Utilize evidence-based and guideline recommendations for neoadjuvant and adjuvant treatments and appropriate treatment sequencing strategies for patients with HER2-positive breast cancer
  4. Develop a strong patient-provider collaborative approach to managing patients with breast cancer that includes multidisciplinary management, patient education, engagement, and shared decision making

Activity Description

Breast cancer is expected to affect over 250,000 American women in 2017, making it the most common cancer in women.1 When the disease is confined to the breast and regional lymph nodes, it is frequently curable. However, metastatic disease is significantly more challenging to treat and accounts for the majority of the over 40,000 breast cancer associated deaths in the United States per year.1 Contributing to this treatment challenge are the estimated 18% to 20% of patients with invasive breast cancer who overexpress the human epidermal growth factor receptor 2 (HER2), which is associated with more aggressive disease and poorer prognosis, but a markedly better response to the combination of chemotherapy and targeted agents.2 Over the last 2 decades, a number of advances have been made for treating patients with HER2-positive breast cancer, which has significantly improved outcomes in both early- and late-stage disease. However, resistance to HER2-targeted therapies and understanding the mechanisms contributing to a less than optimal response continues to be a challenge. Newer therapies are being developed to meet this need that have the potential to shift the treatment paradigm for patients with HER2-positive breast cancer. For now, the appropriate use of treatment guidelines, incorporation of evolving targeted treatment paradigms, and the ability to engage the patient in the decision-making process around therapeutic options, are key to improving outcomes for patients with HER2-positive breast cancer.

This activity is designed to be interactive and fast-paced, allowing you to test your knowledge and practice through a series of multiple choice questions. The activity includes case vignettes, an opportunity to compare yourself to your peers, and to learn what the expert has to say about treatment approaches in HER2-positive breast cancer.

References:

  1. Siegel RL, Miller KD, Jemal A. Cancer Statistics. 2017. CA Cancer J Clin. 2017;67(1):7-30.
  2. Santa-Maria CA, Nye L, Mutonga MB, Jain S, Gradishar WJ. Management of Metastatic HER2-Positive Breast Cancer: Where Are We and Where Do We Go From Here? Oncology (Williston Park). 2016;30(2):148-155.

Faculty

Hope S. Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA


Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Hope S. Rugo, MD, has affiliations with Eisai, Genentech, Lilly, Macrogenics, Merck, Novartis, OBI Pharma, Pfizer, and Plexxikon – all funding to UC Regents only (Contracted Research).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

RMEI Medical Education, LLC
Carrie Noriega, MD, has no affiliations with commercial interests to disclose.
Lobna M. Eldasher, PharmD, has no affiliations with commercial interests to disclose.
Sharon Powell, has no affiliations with commercial interests to disclose.

Postgraduate Institute for Medicine

The PIM planners and managers, Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, MBA, MSN, RN; and Jan Schultz, MSN, RN, CHCP, have nothing to disclose. 

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour.

Designated for 0.5 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, registered nurses, and physician assistants are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, registered nurses, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Technical Support

For any technical issues or issues with your CME Certificate, please visit: http://www.realcme.com/cms/support-center.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
0.25 CME
University of Nebraska Medical Center
Podium to Practice: Updates from San Antonio in the Treatment of Breast Cancer – Focus on HR+/HER2- Disease

Podium to Practice: Updates from San Antonio in the Treatment of Breast Cancer – Focus on HR+/HER2- Disease

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit
Released: December 29, 2017
Expires: December 29, 2018
15 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Provider

This activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend

  

Target Audience

The target audience for this activity is community and academic medical oncologists, advanced practitioners, and other clinicians who treat patients with breast cancer.

Learning Objectives

  • Review the current therapeutic landscape of HR+/HER2- breast cancer
  • Evaluate recently released clinical trial data of current and emerging agents undergoing examination in patients with HR+/HER2- breast cancer
  • Discuss how recently released clinical trial data can be integrated into the treatment armamentarium
  • Develop strategies for the individualized treatment of patients with breast cancer based on efficacy and safety data, as well as patient and disease characteristics

Activity Description

Podium to Practice is an interview involving 2 world renowned experts actively engaged in treatment of patients with breast cancer. They provide expert summary and interpretation of data presented during the 2017 breast cancer conference in San Antonio, as well as provide guidance on the optimal use of current and emerging therapies.

Statement of Educational Need

Due to the volume of research in the treatment of breast cancer, clinicians are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Clinicians need expert guidance to assess the benefits of agents for HR+/HER2- breast cancer, to use existing and novel ones safely and effectively, and to plan for optimal integration of new ones as they become available.

Agenda

  • Introduction
  • Current approaches to the care of HR+/HER2- advanced breast cancer
  • MONALESSA-7, Abstract GS2-05
  • neoMONARCH, Abstract PD5-01
  • ABCSG-16, Abstract GS3-01
  • TEXT and SOFT, Abstracts GS4-02 and GS4-03
  • Points to Ponder

Moderator

Mathew N. Beshara, MD
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

No financial relationships to disclose


Faculty

Sara A. Hurvitz, MD
Associate Professor, Division of Hematology-Oncology, Department of Medicine
David Geffen School of Medicine at UCLA
Co-Director, Santa Monica-UCLA Outpatient Oncology Practice
Medical Director, Clinical Research
UCLA Jonsson Comprehensive Cancer Center
Director, Breast Oncology Program
Division of Hematology-Oncology, UCLA
Los Angeles, California

Grants/Research Support: Amgen Inc., Bayer Healthcare Pharmaceuticals LLC, BioMarin, Boehringer Ingelheim, Cascadian Therapeutics, Dignitana AB, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline plc, Merrimack, Medivation, Inc., Novartis, OBI Pharma, Inc., Pfizer Inc, Puma Biotechnology, Inc, Seattle Genetics, Inc.

Other: Bayer Healthcare Pharmaceuticals LLC, Eli Lilly and Company, Novartis, OBI Pharma, Inc.


Hope S. Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Grants/Research Support: Eisai Co., Ltd, Eli Lilly and Company, Genentech/Roche, OBI Pharma, Inc., Pfizer Inc, Plexxikon, Merck & Co., Inc, Novartis


Conflict of Interest Policy/Disclosure Statement

As a provider accredited by ACCME, the University of Nebraska Medical Center (UNMC), Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC, Center for Continuing Education.

The following indicates the disclosure declaration information and the nature of those commercial relationships.

All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation. Participants who complete the educational activity, pre-/post-test and evaluation will receive a certificate of credit.

Statement of Commercial Support

Educational grant support provided by Novartis.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

University of Nebraska Medical Center, Center for Continuing Education
Brenda Ram, CMP, CHCP
bram@unmc.edu
402-559-9250

Bio Ascend
meetings@bioascend.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / CNE / CPE
AXIS
FAQs on Staying Up to Date on the Treatment of Advanced HR-Positive, HER2-Negative Breast Cancer

FAQs on Staying Up to Date on the Treatment of Advanced HR-Positive, HER2-Negative Breast Cancer

Start

Activity Details

Free CME/CPE/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hours
Released: November 21, 2017
Expires: November 20, 2018
30 minutes to complete

Provided By

This activity is provided by  

Target Audience

This activity is intended for physicians, nurses, pharmacists, and other healthcare professionals who manage breast cancer.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Summarize efficacy data for CDK 4/6 inhibitors in the setting of advanced HR-positive, HER2-negative breast cancer
  • Identify differences in adverse events among the available CDK 4/6 inhibitors
  • Analyze available data to determine appropriate individualized treatment selection for patients with advanced HR-positive, HER2-negative breast cancer

Activity Description

The goal for this activity is to provide an expert perspective on frequently asked questions pertaining to the treatment of advanced HR-positive, HER2-negative breast cancer to help clinicians gain an enhanced understanding of this disease to offer the best possible treatment choices to their patients.

Breast cancers that are hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative represent the most common subtype of breast cancer. Nearly 80% of patients with advanced breast cancer have the HER2-negative subtype and therefore are not candidates for HER2-targeting therapies. Endocrine therapy is currently the cornerstone of treatment for advanced HR-positive breast cancer. However, not all patients respond to first-line endocrine therapy, and those that do respond eventually experience disease relapse. Resistance to endocrine therapy is common, and complete disease resistance to additional endocrine therapy eventually develops in patients with HR-positive metastatic breast cancer (MBC). The 5-year and 10-year survival rates for MBC are 26% and 5% to 10%, respectively. Significant therapeutic advances in this area include the development of agents that target critical pathways involved in the development of resistance to endocrine therapy. These include mechanistic target of rapamycin (mTOR) inhibitors and cyclin-dependent kinase (CDK) 4/6 inhibitors.

This activity will focus on endocrine therapy, CDK 4/6 inhibitors, and treatment selection/sequencing.

Author

Adam M. Brufsky, MD, PhD
Professor of Medicine
Associate Chief, Hematology-Oncology
Associate Director, Translational Research
UPMC Hillman Cancer Center
University of Pittsburgh
Pittsburgh, Pennsylvania


Co-Author

Aju Mathew, MD, MPhil, FACP
Assistant Professor of Medicine
University of Kentucky
Lexington, Kentucky


Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The author, Adam M. Brufsky, MD, PhD reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:  Received consulting fees from Lilly USA, Novartis  Pharmaceuticals Corp, Pfizer, Inc.

The co-author Aju Mathew, MD, MPhil, FACP has no real or apparent financial relationships to report.

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko; Laura Healy; and Marilyn Haas, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. Stephanie Sutphin, PharmD, reports a financial interest/relationship or affiliation in the form of Advisory board: Seattle Genetics and Amgen Biosimilars.

Continuing Education Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Designation of Credit

Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Pharmacists
This application-based activity is approved for 0.5 contact hour of continuing pharmacy education credit. UAN 0592-0000-17-046-H01-P.

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

Statement of Commercial Support

This activity is supported by educational grants from Novartis Pharmaceuticals and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

Disclosure of Unlabeled Use

This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at info@axismeded.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME
Imedex
Interactive Case: Choosing and Using CDK4/6 Inhibitors for Breast Cancer—First-line Therapy

Interactive Case: Choosing and Using CDK4/6 Inhibitors for Breast Cancer—First-line Therapy

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit
Released: November 13, 2017
Expires: November 12, 2018
30 minutes to complete

***This activity was recorded on September 21, 2017. Abemaciclib was subsequently approved by the FDA for use in the treatment of HR+/HER2- breast cancer on September 28, 2017.

Provider

This activity is provided by Imedex, LLC.

Overview

The approvals of palbociclib and ribociclib, the first cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, provided advanced or metastatic hormone-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer patients with promising new treatment options. With a third CDK4/6 inhibitor, abemaciclib, approved in late September 2017, this class of therapy has become the new standard of care for HR+/HER2- breast cancer, which comprises the majority (approximately 75%) of all breast cancer cases. This interactive activity features expert faculty discussing practical aspects of using this class of agents as first-line therapy in HR+/HER2- advanced or metastatic breast cancer.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Describe the mechanisms of CDK4/6 inhibition and its relevance to HR+/HER2- breast cancer
  • Assess the safety and toxicity profiles of each approved and the emerging CDK4/6 inhibitor agent and the resulting needs for different types of monitoring
  • Devise a strategy to encourage patient adherence to a CDK4/6 regimen

Target Audience

This educational activity is designed to meet the educational needs of US-based community medical oncologists and other healthcare professionals involved and/or interested in the management of patients with breast cancer.

Chair

Harold J. Burstein, MD, PhD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts


Faculty

Kimberly L. Blackwell, MD
Duke Cancer Institute
Durham, North Carolina


Continuing Education

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this internet-based enduring educational activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.5 hour of Category 1 credit for completing this program.

In order to receive credit, participants must successfully complete the post-test and complete the online evaluation form. You will receive an online CME statement of credit to print for your records.

Support

Supported by an educational grant from: Novartis Pharmaceuticals Corporation.

Disclosure of Financial Relationships

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), Imedex, LLC must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are instructed to provide a balanced view of therapeutic options by utilizing generic names to ensure impartiality.

Faculty Disclosures

All faculty participating in an Imedex activity are required to disclose relevant financial relationships that may be considered to be related to the subject matter of the educational activity. Disclosure of these commitments and/or relationships is included in these course materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

The following indicates the faculty disclosure declaration information and the nature of those commercial relationships.

1=grant/research support 2=consultant 3=speaker’s bureau 4=stock shareholder 5=other support
Kimberly L. Blackwell, MD:  Lilly(2), Novartis Pharmaceuticals Corporation(2), Pfizer(2)

The following speakers do not report any affiliation:
Harold J. Burstein, MD, PhD                 

All materials are included with the permission of the authors.

Imedex Staff Disclosures

All Imedex staff members who are in a position to control content of this activity have no financial relationships with any commercial interests, except for the following individuals:

Chris Bolwell owns shares of stock of GlaxoSmithKline.

Unapproved Uses

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.

The opinions expressed in this webcast are the opinions of the authors and do not necessarily reflect the opinions of Imedex.

Disclaimer

The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

About Imedex

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

© 2017 Imedex, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.

For comments or inquiries, please contact:
Imedex, LLC
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Fax: +1(770) 751-7334
Email: elearning@imedex.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME
Imedex
Interactive Case: Choosing and Using CDK4/6 Inhibitors for Breast Cancer—Second-line Therapy

Interactive Case: Choosing and Using CDK4/6 Inhibitors for Breast Cancer—Second-line Therapy

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit
Released: November 13, 2017
Expires: November 12, 2018
30 minutes to complete

***This activity was recorded on September 21, 2017. Abemaciclib was subsequently approved by the FDA for use in the treatment of HR+/HER2- breast cancer on September 28, 2017.

Provider

This activity is provided by Imedex, LLC.

Overview

The approvals of palbociclib and ribociclib, the first cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, provided advanced or metastatic hormone-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer patients with promising new treatment options. With a third CDK4/6 inhibitor, abemaciclib, approved in late September 2017, this class of therapy has become the new standard of care for HR+/HER2- breast cancer, which comprises the majority (approximately 75%) of all breast cancer cases. This interactive activity features expert faculty discussing practical aspects of using this class of agents as second-line therapy in HR+/HER2- advanced or metastatic breast cancer.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Describe the mechanisms of CDK4/6 inhibition and its relevance to HR+/HER2- breast cancer
  • Assess the safety and toxicity profiles of each approved and the emerging CDK4/6 inhibitor agent and the resulting needs for different types of monitoring
  • Devise a strategy to encourage patient adherence to a CDK4/6 regimen

Target Audience

This educational activity is designed to meet the educational needs of US-based community medical oncologists and other healthcare professionals involved and/or interested in the management of patients with breast cancer.

Chair

Harold J. Burstein, MD, PhD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts


Faculty

Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research,
Baylor University Medical Center
Texas Oncology
Co-Chair, Breast Cancer Research Program,
The US Oncology Network
The Woodlands, Texas


Continuing Education

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this internet-based enduring educational activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.5 hour of Category 1 credit for completing this program.

In order to receive credit, participants must successfully complete the post-test and complete the online evaluation form. You will receive an online CME statement of credit to print for your records.

Support

Supported by an educational grant from: Novartis Pharmaceuticals Corporation.

Disclosure of Financial Relationships

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), Imedex, LLC must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are instructed to provide a balanced view of therapeutic options by utilizing generic names to ensure impartiality.

Faculty Disclosures

All faculty participating in an Imedex activity are required to disclose relevant financial relationships that may be considered to be related to the subject matter of the educational activity. Disclosure of these commitments and/or relationships is included in these course materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

The following indicates the faculty disclosure declaration information and the nature of those commercial relationships.

1=grant/research support 2=consultant 3=speaker’s bureau 4=stock shareholder 5=other support
Joyce O'Shaughnessy, MD: AstraZeneca(2), Celegene(2), Lilly(2), Novartis Pharmaceuticals Corporation(2,3), Pfizer(2)

The following speakers do not report any affiliation:
Harold J. Burstein, MD, PhD                 

All materials are included with the permission of the authors.

Imedex Staff Disclosures

All Imedex staff members who are in a position to control content of this activity have no financial relationships with any commercial interests, except for the following individuals:

Chris Bolwell owns shares of stock of GlaxoSmithKline.

Unapproved Uses

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.

The opinions expressed in this webcast are the opinions of the authors and do not necessarily reflect the opinions of Imedex.

Disclaimer

The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

About Imedex

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

© 2017 Imedex, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.

For comments or inquiries, please contact:
Imedex, LLC
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Fax: +1(770) 751-7334
Email: elearning@imedex.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.